雷递网 雷建平 1月22日上海复星医药(集团)股份有限公司(证券代码:600196,股票简称:复星医药)今日发布公告,称2025年1月22日,吸收合并作为特别决议案于复宏汉霖临时股东大会上获出席会议的三分之二以上(含本数)有表决权股东的批准,但于仅由独立H股股东享有表决权的复宏汉霖H股类别股东大会上未获通过。因此,本次交易协议的生效条件未获达成,吸收合并将不予实施,复宏汉霖将保留H股上市地位。这...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.